Search news stories
Enter a keyword to search news.
Over the last few months our student group has doubled in size with the arrival of four new PhD candidates: Manjit Rana, Dana Al Safadi, Ahmed Aldoghachi, and Reza Maleki. The ‘class of 2023’ joins our current PhD students Wenjun Nora Liu, Alex Pace, Maliha Wajahat and our 2023 Honours student, Maria Bettina Sablan. All the best for your research studies!
DRMCRL researchers are attending and presenting at the 32nd International Association for Breast Cancer Research Conference (IABCR 2023) in Tulum, Mexico.
In 2024, we will be celebrating the 21st anniversary of the International Pacific Rim (PacRim) Breast and Prostate Cancer Meeting series, twenty-one years after the inaugural PacRim Meeting was held in southern Australia.
The Florey Postgraduate Research Conference, held on 21 September at the Adelaide Convention Centre, was a highlight for the Faculty of Health and Medical Sciences Faculty showcasing outstanding research activity. DRMCRL PhD student Wenjun (Nora) Liu was awarded the Florey Medical Research Foundation (Applied) prize for achieving the highest score in the applied science field for her poster presentation “Make sense of noisy patient-derived data: A novel workflow for deconvoluting bulk RNA-seq data to unveil transcriptional responses to androgen in breast tissues". Well done Nora! The conference, now in its 16th year, gives HDR students the opportunity to discuss their research with fellow students, academics, industry partners, and other major stakeholders of the University. It is a chance to recognise excellent in research, hear from distinguished speakers on specialised topics, and beneficial to HDR students for ongoing professional and personal development. 2022 Florey Postgraduate Conference prize list here. See Nora on Twitter here.
Cancer Australia funding for arming androgen receptors to transform endocrine therapy for ER+ breast cancer
Associate Professor Theresa Hickey and her team have received $600,000 from Cancer Australia to support research to examine the complex interaction between estrogen and androgen to develop new, more effective strategies for treating breast cancer, with potential to also improve quality of life.
Breast Cancer Trials (BCT) held their 43rd Annual Scientific Meeting in Melbourne on July 27-30.
In the Translational Research session at this meeting, Prof Wayne Tilley, Director of the Dame Roma Mitchell Cancer Research Laboratories (DRMCRL) presented work on "Understanding the role of the androgen receptor" as targeting the androgen receptor (AR) in breast cancer has been of intense clinical interest over the past two decades.
DRMCRL lab members participated in the NBCF 2022 Mothers Day Classic (MDC) with a 5km River Torrens circuit, and for the fourth straight year have won the trophy for the Largest Higher Education Team in South Australia.
DRMCRL Director, Prof Wayne Tilley and Prof Charlotte Bevan (Imperial College London) co-chaired the 3rd Nuclear Receptor meeting, which returned to a face to face format in Cancun, Mexico, after being postponed for the last two years.
Associate Professor Alex Swarbrick presented at the Adelaide Medical School Distinguished Speaker Series 2022
Associate Professor Alex Swarbrick, Senior Principal Research Fellow and co-leader of the Strategic program in Dynamic Cancer Ecosystems, Garvan Institute of Medical Research, Sydney presented a seminar entitled "Solid tumours as cellular ecosystems: new insights into disease stratification and treatment", on 7 April, 2022, in the AHMS Building, University of Adelaide. The seminar covered how new technologies, including single cell sequencing and high-dimensionality tissue analysis, are enabling new insights into cancer ecosystems, leading to advances in the stratification and treatment of solid cancers. A/Prof Swarbrick is a developmental biologist with a long-standing interest in how cells in developing embryos control the decision to divide or to differentiate in co-ordination with cell cycle events, as well as how this co-ordination is subverted in cancers. The seminar was hosted by Prof Wayne Tilley, DRMCRL Director.
Research from Prof Tilley’s laboratory on “Nuclear receptor biology in castration resistant prostate cancer” was presented at the 28th Annual Prostate Cancer Foundation (PCF) Scientific Retreat, Carlsbad, USA in November, 2021. In a session that focused on nuclear receptor biology, including the role of GR in CRPC and its potential as a therapeutic target, as well as the impact of AR agonism in prostate cancer and ER-positive breast cancer, Prof Tilley presented data that suggested a role for potent AR agonists and that warranted further study into the potential for selective AR modulators in the treatment of breast and prostate cancer. His paper formed part of the PCF’s State of Science Report. In addition, the PCF Retreat Scientific Meeting Report will be published in the scientific journal, The Prostate.